Abstract YO17
Case summary
Serous ovarian cancer accounts for 80% of ovarian cancer, most of them being high grade and the expected survival for recurrent disease is less than 12 months. CDK4/6 inhibitor has shown promising benefit in ER-positive metastatic breast cancer. A phase II trial showed that investigating palbociclib in recurrent ovarian cancer has shown tolerable toxicity profile and radiological median PFS of 3.7 months and Gynecologic Cancer InterGroup CA125 criteria median PFS of 4.0 months. Therefore CDK4/6 inhibitors used alone or as combination could be useful in recurrent ovarian cancer. We report a case of recurrent ovarian cancer treated with palbociclib and letrozole.
Madam X was initially diagnosed with stage 3 ovarian cancer in 1994 at 25-years-old. She underwent TAHBSO, infracolic omentectomy followed by adjuvant carboplatin/paclitaxel. She was disease-free for 19 years until 2013 when she presented with pleural effusion which was confirmed to be recurrent papillary serous carcinoma. She received carboplatin/paclitaxel/bevacizumab combination for 8 months and stopped in view that the patient opted for a drug holiday. In 2016, her pleural effusion worsened. BRCA testing showed no BRCA1/2 mutation. She was then treated with carboplatin & pegylated liposomal doxorubicin for 6 cycles.
In April 2017, she presented with left axillary lymphadenopathy. Core biopsy showed high-grade serous carcinoma, positive for ER & PR; negative for HER2, PDL1 and MSI. She was then commenced on letrozole.
In May 2017, her CA15-3 was increasing from 55U/mL to 77U/mL, and letrozole was changed to tamoxifen. However, CA15-3 continued to rise to 113U/mL within a month. Her performance status was ECOG 0. She was then commenced on palbociclib 125mg OD 3 weeks on and 1 week off schedule with letrozole 2.5mg OD since June 2017. She tolerated palbociclib well and did not require any dose adjustments. The adverse events reported were grade 2 leucopenia and grade 2 neutropenia. CA 15-3 remained to respond for 14 months and she is still ongoing treatment.
In this case, palbociclib and letrozole have shown a prolonged PFS of more than 14 months and an excellent toxicity profile. This could present a potential therapeutic role of CDK4/6 inhibition in recurrent ovarian cancers.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival
Presenter: Chavapon Ngokngarm
Session: Poster display session
Resources:
Abstract
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract